Unknown

Dataset Information

0

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia.

ABSTRACT:

SUBMITTER: Izzedine H 

PROVIDER: S-EPMC9751673 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia.

Izzedine Hassan H   Brocheriou Isabelle I   Mathian Alexis A   Ghez David D   Amoura Zahir Z  

Kidney international reports 20220912 11

Similar Datasets

Unknown Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
| S-EPMC8670015 | biostudies-literature
Unknown Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
| S-EPMC4862586 | biostudies-literature
Unknown Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.
| S-EPMC8721287 | biostudies-literature
Unknown P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
| S-EPMC10429535 | biostudies-literature
Unknown Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia.
| S-EPMC8176161 | biostudies-literature
Unknown Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
| S-EPMC6517672 | biostudies-literature
Unknown Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
| S-EPMC10424141 | biostudies-literature
Unknown Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
| S-EPMC7146022 | biostudies-literature
Unknown Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
| S-EPMC9666115 | biostudies-literature
Unknown Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
| S-EPMC8301526 | biostudies-literature